The role of growth factor-induced changes in cell fate in prostate cancer progression

Systems Biology of Cancer

Volumn , Issue , 2015, Pages 361-376

  Yu, Min ^a   Smolen, Gromoslaw A ^a   Haber, Daniel A ^a   Maheswaran, Shyamala ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941360024     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/9780511979811.024     Document Type: Chapter

References (144)

1. Abate-Shen, C., and Shen, M.M. (2007). FGF signaling in prostate tumorigenesis: new insights into epithelial-stromal interactions. Cancer Cell 12, 495-497.
2. Acevedo, V.D., Gangula, R.D., Freeman, K.W., et al. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial- to-mesenchymal transition. Cancer Cell 12, 559-571.
3. Aigner, K., Dampier, B., Descovich, L., et al. (2007). The transcription factor ZEB1 (deltaEFl) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26, 6979-6988.
4. Allard, S., Adin, P., Gouedard, L., et al. (2000). Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin. Development 127, 3349-3360.
5. Angelucci, A., Gravina, G.L., Rucci, N., et al. (2006). Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13, 197-210.
6. Ao, M., Williams, K., Bhowmick, N.A., and Hayward, S.W. (2006). Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66, 8007-8016.
7. Aumuller, G. (1983). Morphologic and endocrine aspects of prostatic function. Prostate 4, 195-214.
8. Aumuller, G. (1989). Morphologic and regulatory aspects of prostatic function. Anat Embryol 179, 519-531.
9. Batlle, E., Sancho, E., Franci, C., et al. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84-89.
10. Berx, G., Becker, K.F., Hofler, H., and van Roy, F. (1998). Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12, 226-237.
11. Bonano, V.I., Oltean, S., and Garcia- Blanco, M.A. (2007). A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice. Nat Protoc 2, 2166-2181.
12. Bonci, D., Coppola, V., Musumeci, M., et al. (2008). The miR-15a-miR- 16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14, 1271-1277.
13. Bruxvoort, K.J., Charbonneau, H.M., Giambernardi, T.A., et al. (2007). Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67, 2490-2496.
14. Buijs, J.T., Henriquez, N.V., van Overveld, P.G., et al. (2007a). TGF- beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24, 609-617.
15. Buijs, J.T., Rentsch, C.A., van der Horst, G., et al. (2007b). BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171, 1047-1057.
16. Calin, G.A., Dumitru, C.D., Shimizu, M., et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99, 15524-15529.
17. Calin, G.A., Ferracin, M., Cimmino, A., et al. (2005). A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353, 1793-1801.
18. Cano, A., Perez-Moreno, M.A., Rodrigo, I., et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83.
19. Catalano, A., Rodilossi, S., Rippo, M.R., Caprari, P., and Procopio, A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 279, 46706-46714.
20. Chen, G., Shukeir, N., Potti, A., et al. (2004). Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101, 1345-1356.
21. Chen, M., Chen, L.M., and Chai, K.X. Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate 66, 911-920.
22. Chen, M., Tanner, M., Levine, A.C., et al. (2009). Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 8, 149-157.
23. Chu, J.H., Yu, S., Hayward, S.W., and Chan, F.L. (2009). Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelialmesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate 69, 428-442.
24. Clark, J.P., and Cooper, C.S. (2009). ETS gene fusions in prostate cancer. Nat Rev Urol 6, 429-439.
25. Cunha, G.R. (1972a). Epithelio- mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 172, 179-195.
26. Cunha, G.R. (1972b). Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin. Anat Rec 172, 529-541.
27. Cunha, G.R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74, 1030-1044.
28. Cunha, G.R., Bigsby, R.M., Cooke, P.S., and Sugimura, Y. (1985). Stromal- epithelial interactions in adult organs. Cell Differ 17, 137-148.
29. Cunha, G.R., Donjacour, A.A., and Sugimura, Y. (1986). Stromal- epithelial interactions and heterogeneity of proliferative activity within the prostate. Biochem Cell Biol 64, 608-614.
30. Darby, S., Sahadevan, K., Khan, M.M., et al. (2006). Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene25, 4122-4127.
31. Datta, S., and Datta, M.W. (2006). Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci 63, 435-448.
32. Dhanasekaran, S.M., Barrette, T.R., Ghosh, D., et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
33. Dhanasekaran, S.M., Dash, A., Yu, J., et al. (2005). Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 19, 243-245.
34. Di Lorenzo, G., Tortora, G., D’Armiento, F.P., et al. (2002). Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res8, 3438-3444.
35. Drake, J.M., Strohbehn, G., Bair, T.B., Moreland, J.G., and Henry, M.D. (2009). ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell 20, 2207-2217.
36. Eger, A., Aigner, K., Sonderegger, S., et al. (2005). DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24, 2375-2385.
37. Fan, L., Pepicelli, C.V., Dibble, C.C., et al. (2004). Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145, 3961-3970.
38. Feeley, B.T., Krenek, L., Liu, N., et al. (2006). Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38, 154-166.
39. Feldmann, G., Dhara, S., Fendrich, V., et al. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67, 2187-2196.
40. Gandellini, P., Folini, M., Longoni, N., et al. (2009). miR-205 exerts tumor- suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 69, 2287-2295.
41. Graham, T.R., Zhau, H.E., Odero-Marah, V.A., et al. (2008). Insulin-like growth factor-I- dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68, 2479-2488.
42. Gravdal, K., Halvorsen, O.J., Haukaas, S.A., and Akslen, L.A. (2007). A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13, 7003-7011.
43. Gu, X., Zerbini, L.F., Otu, H.H., et al. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67, 4219-4226.
44. Guaita, S., Puig, I., Franci, C., et al. (2002). Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. JBiol Chem 277, 39209-39216.
45. Gupta, S., Iljin, K., Sara, H., et al. (2010). FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70, 6735-6745.
46. Hall, C.L., Kang, S., MacDougald, O.A., and Keller, E.T. (2006). Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97, 661-672.
47. Hamdy, F.C., Autzen, P., Robinson, M.C., et al. (1997). Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57, 4427-4431.
48. Hawksworth, D., Ravindranath, L., Chen, Y., et al. (2010). Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13, 311-315.
49. Hay, E.D. (1995). An overview of epithelio-mesenchymal transformation. Acta Anat 154, 8-20.
50. Hayward, S.W., and Cunha, G.R. (2000). The prostate: development and physiology. Radiol Clin North Am 38, 1-14.
51. He, T.C., Sparks, A.B., Rago, C., et al. (1998). Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512.
52. Hirohashi, S. (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153, 333-339.
53. Hogan, B.L. (1999). Morphogenesis. Cell 96, 225-233.
54. Horvath, L.G., Lelliott, J.E., Kench, J.G., et al. (2007). Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 67, 1081-1090.
55. Irie, H.Y., Pearline, R.V., Grueneberg, D., et al. (2005). Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelialmesenchymal transition. J Cell Biol 171, 1023-1034.
56. Ittman, M., and Mansukhani, A. (1997). Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 157, 351-356.
57. Jacob, L., and Lum, L. (2007). Hedgehog signaling pathway. Sci STKE 2007, cm6.
58. Jiang, J., and Hui, C.C. (2008). Hedgehog signaling in development and cancer. Dev Cell 15, 801-812.
59. Kajita, M., McClinic, K.N., and Wade, P.A. (2004). Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24, 7559-7566.
60. Karhadkar, S.S., Bova, G.S., Abdallah, N., et al. (2004). Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712.
61. Katoh, Y., and Katoh, M. (2008). Hedgehog signaling, epithelial-to- mesenchymal transition and miRNA (review). Int J Mol Med 22, 271-275.
62. Kharait, S., Dhir, R., Lauffenburger, D., and Wells, A. (2006). Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 343, 848-856.
63. Kim, H.G., Kassis, J., Souto, J.C., Turner, T., and Wells, A. (1999). EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14, 1175-1182.
64. Klocker, H., Culig, Z., Kaspar, F., et al. (1994). Androgen signal transduction and prostatic carcinoma. World J Urol 12, 99-103.
65. Krueckl, S.L., Sikes, R.A., Edlund, N.M., et al. (2004). Increased insulin-like growth factor I receptor expression and signaling are components of androgenindependent progression in a lineage-derived prostate cancer progression model. Cancer Res 64, 8620-8629.
66. Kumar, V.L., and Majumder, P.K. (1995). Prostate gland: structure, functions and regulation. Int Urol Nephrol 27, 231-243.
67. Kwabi-Addo, B., Ozen, M., and Ittmann, M. (2004). The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11, 709-724.
68. Kwok, W.K., Ling, M.T., Lee, T.W., et al. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65, 5153-5162.
69. La Rocca, G., Badin, M., Shi, B., et al. (2009). Mechanism of growth inhibition by microRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol 220, 485-491.
70. Lamm, M.L., Catbagan, W.S., Laciak, R.J., et al. (2002). Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. Dev Biol 249, 349-366.
71. Lapointe, J., Li, C., Higgins, J.P., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
72. LaTulippe, E., Satagopan, J., Smith, A., et al. (2002). Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62, 4499-4506.
73. Liu, Y., El-Naggar, S., Darling, D.S., Higashi, Y., and Dean, D.C. (2008). Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579-588.
74. Lo, H.W., Hsu, S.C., Xia, W., et al. (2007). Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelialmesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res67, 9066-9076.
75. Lu, S., Lee, J., Revelo, M., Wang, X., and Dong, Z. (2007). Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res13, 5692-5702.
76. Lu, Z., Ghosh, S., Wang, Z., and Hunter, T. (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta- catenin, and enhanced tumor cell invasion. Cancer Cell 4, 499-515.
77. Maestro, R., Dei Tos, A.P., Hamamori, Y., et al. (1999). Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13, 2207-2217.
78. Mani, S.A., Guo, W., Liao, M.J., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
79. Mani, S.A., Yang, J., Brooks, M., et al. (2007). Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104, 10069-10074.
80. Maretzky, T., Reiss, K., Ludwig, A., et al. (2005). ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 102, 9182-9187.
81. Massague, J. (2008). TGFbeta in cancer. Cell 134, 215-230.
82. Matsubara, A., Kan, M., Feng, S., and McKeehan, W.L. (1998). Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 58, 1509-1514.
83. Memarzadeh, S., Xin, L., Mulholland, D.J., et al. (2007). Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12, 572-585.
84. Mendell, J.T. (2008). miRiad roles for the miR-17-92 cluster in development and disease. Cell 133, 217-222.
85. Miki, T., Bottaro, D.P., Fleming, T.P., et al. (1992). Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 89, 246-250.
86. Morali, O.G., Delmas, V., Moore, R., et al. (2001). IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20, 4942-4950.
87. Mori, K., Le Goff, B., Charrier, C., et al. (2007). DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40, 981-990.
88. Nagrath, S., Sequist, L.V., Maheswaran, S., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239.
89. Odero-Marah, V.A., Wang, R., Chu, G., et al. (2008). Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18, 858-870.
90. Olmeda, D., Jorda, M., Peinado, H., Fabra, A., and Cano, A. (2007). Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 26, 1862-1874.
91. Oltean, S., Febbo, P.G., and Garcia- Blanco, M.A. (2008). Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. Clin Exp Metastasis 25, 611-619.
92. Oltean, S., Sorg, B.S., Albrecht, T., et al. (2006). Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 103, 14116-14121.
93. Playford, M.P., Bicknell, D., Bodmer, W.F., and Macaulay, V.M. (2000). Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 97, 12103-12108.
94. Prins, G.S., and Putz, O. (2008). Molecular signaling pathways that regulate prostate gland development. Differentiation 76, 641-659.
95. Rajan, R., Vanderslice, R., Kapur, S., et al. (1996). Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28, 1-9.
96. Reiss, K., D’Ambrosio, C., Tu, X., Tu, C., and Baserga, R. (1998). Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4, 2647-2655.
97. Richmond, P.J., Karayiannakis, A.J., Nagafuchi, A., Kaisary, A.V., and Pignatelli, M. (1997). Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57, 3189-3193.
98. Sabbisetti, V.S., Chirugupati, S., Thomas, S., et al. (2005). Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer 117, 551-560.
99. Sakai, D., Suzuki, T., Osumi, N., and Wakamatsu, Y. (2006). Cooperative action of Sox9, Snail2 and PKA signaling in early neural crest development. Development 133, 1323-1333.
100. Schaefer, A., Jung, M., Mollenkopf, H.J., et al. (2010). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126, 1166-1176.
101. Shah, G.V., Muralidharan, A., Gokulgandhi, M., Soan, K., and Thomas, S. (2009). Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin- calcitonin receptor axis in prostate cancer. J Biol Chem 284, 1018-1030.
102. Sheng, T., Li, C., Zhang, X., et al. (2004). Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer3, 29.
103. Spaderna, S., Schmalhofer, O., Wahlbuhl, M., et al. (2008). The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68, 537-544.
104. Strathdee, G. (2002). Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 12, 373-379.
105. Szczyrba, J., Loprich, E., Wach, S., et al. (2010). The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8, 529-538.
106. Thiery, J.P. (2002). Epithelialmesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454.
107. Thiery, J.P. (2003). Epithelialmesenchymal transitions in development and pathologies. Curr Opin Cell Biol15, 740-746.
108. Thomas, S., Chigurupati, S., Anbalagan, M., and Shah, G. (2006). Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol 20, 1894-1911.
109. Thompson, T.C. (1990). Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345-354.
110. Thomson, S., Buck, E., Petti, F., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65, 9455-9462.
111. Tomita, K., van Bokhoven, A., van Leenders, G.J., et al. (2000). Cadherin switching in human prostate cancer progression. Cancer Res 60, 3650-3654.
112. Tomlins, S.A., Mehra, R., Rhodes, D.R., et al. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39, 41-51.
113. Truica, C.I., Byers, S., and Gelmann, E.P. (2000). Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60, 4709-4713.
114. Turner, T., Chen, P., Goodly, L.J., and Wells, A. (1996). EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14, 409-418.
115. Umbas, R., Isaacs, W.B., Bringuier, P.P., et al. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54, 3929-3933.
116. Umbas, R., Schalken, J.A., Aalders, T.W., et al. (1992). Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52, 5104-5109.
117. Uziel, T., Karginov, F.V., Xie, S., et al. (2009). The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl AcadSci USA 106, 2812-2817.
118. Valta, M.P., Hentunen, T., Qu, Q., et al. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology 147, 2171-2182.
119. Valta, M.P., Tuomela, J., Bjartell, A., et al. (2008). FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 123, 22-31.
120. Varjosalo, M., and Taipale, J. (2008). Hedgehog: functions and mechanisms. Genes Dev 22, 2454-2472.
121. Vega, S., Morales, A.V., Ocana, O.H., et al. (2004). Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18, 1131-1143.
122. Verras, M., and Sun, Z. (2006). Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237, 22-32.
123. Wang, H., Leav, I., Ibaragi, S., et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 68, 1625-1630.
124. Wang, X., Ling, M.T., Guan, X.Y., et al. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23, 474-482.
125. Wilding, G. (1992). The importance of steroid hormones in prostate cancer. Cancer Surv 14, 113-130.
126. Wissmann, C., Wild, P.J., Kaiser, S., et al. (2003). WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201, 204-212.
127. Wong, Y.C., and Wang, Y.Z. (2000). Growth factors and epithelial- stromal interactions in prostate cancer development. Int Rev Cytol 199, 65-116.
128. Xu, J., Wang, R., Xie, Z.H., et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66, 1664-1673.
129. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W.L. (1993). Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13, 4513-4522.
130. Yang, F., Li, X., Sharma, M., et al. (2002). Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277, 11336-11344.
131. Yang, J., Mani, S.A., Donaher, J.L., et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
132. Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14, 818-829.
133. Yang, S., Zhong, C., Frenkel, B., Reddi, A.H., and Roy-Burman, P. (2005). Diverse biological effect and Smad Wang, L., Tang, H., Thayanithy, V., et al. (2009). Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69, 9490-9497.of microRNA-145 in prostate cancer. Br J Cancer 103, 256-264.
134. Zeisberg, M., Hanai, J., Sugimoto, H., et al. (2003). BMP-7 counteracts TGF-betal-induced epithelial-to- mesenchymal transition and reverses chronic renal injury. Nat Med 9, 964-968.
135. Zhan, Y., Fujino, A., MacLaughlin, D.T., et al. (2006). Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. Development 133, 2359-2369.
136. Zhau, H.E., Odero-Marah, V., Lue, H.W., et al. (2008). Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25, 601-610.
137. Zhau, H.Y., Chang, S.M., Chen, B.Q., et al. (1996). Androgen-repressed signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65, 5769-5777.
138. Yates, C., Wells, A., and Turner, T. (2005). Luteinising hormonereleasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 92, 366-375.
139. Yates, C.C., Shepard, C.R., Stolz, D.B., and Wells, A. (2007). Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 96, 1246-1252.
140. Yuen, H.F., Chua, C.W., Chan, Y.P., et al. (2007). Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50, 648-658.
141. Zaman, M.S., Chen, Y., Deng, G., et al. (2010). The functional significance phenotype in human prostate cancer. Proc Natl Acad Sci USA 93, 15152-15157.
142. Zhu, H., Mazor, M., Kawano, Y., et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res 64, 7918-7926.
143. Zi, X., Guo, Y., Simoneau, A.R., et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65, 9762-9770.
144. Zolfaghari, A., and Djakiew, D. (1996). Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function. Prostate 28, 232-238.